FOR PATIENTS
FOR CLINICIANS
FOR THE PRESS
THE EXPERTS GROUP
MEDIA POOL
> SIRT > Home > SIRT studies
 

SIRT STUDIES

Selective Internal Radiation Therapy (SIRT) has been licensed in Europe since 2002 for the treatment of inoperable liver cancer and liver metastases. More than 4,000 patients have since received SIRT in Germany, Austria and Switzerland. Numerous surveys and clinical studies confirm the method’s effectiveness and tolerability. Clinicians in the three German-speaking countries are currently carrying out important clinical SIRT studies in order to further confirm the efficiency and safety of radioembolisation (RE). They are checking, among other things, the extent to which SIRT, when used in combination with systemic chemotherapy, can prolong overall survival or whether it delivers greater treatment success compared to chemotherapy.

 

Below are the key SIRT studies in the German-speaking region:

 

SORAMIC

EXPLOSIVE

 

In addition to the studies mentioned here, there are many other clinical trials currently taking place worldwide involving SIRT.

 
NEWS & DATES
More treatment options are necessary for patients with metastatic colorectal cancer – Colorectal cancer prevention is getting more and more attention. However, every third colorectal cancer patient develops metastases in the course of the disease – often in the liver. For these patients, more and better therapy options are needed. Local therapies offer promising opportunities.To the press release
The new ESMO guidelines recommend SIRT for people with metastatic colorectal cancer if the metastases are limited to the liver and are not responding to chemotherapy.
New evidence of the benefits of SIRT in mCRC – The depth-of-response data from the SIRFLOX study shows a significantly larger local depth of response through the combination of SIRT and chemotherapy. To the press release
Metastatic colorectal cancer: the SIRFLOX, FOXFIRE and FOXFIRE Global studies are investigating the benefits of combining SIRT with chemotherapy. The data from the three studies regarding overall survival is expected by the end of 2017. The SARAH and SIRveNIB studies on advanced liver cell cancer are now complete. Both compared Y90 radio-embolisation with sorafenib chemotherapy. The initial results are set to be published at the end of 2016 (SARAH) and 2017 (SIRveNIB).
The SIRT Experts Group is a partner of: